|
|
Volumn 28, Issue 5, 2010, Pages 383-384
|
|
Biomarker-led adaptive trial blazes a trail in breast cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE;
AMG 386;
AMG 655;
ANTINEOPLASTIC AGENT;
BIOLOGICAL MARKER;
CONATUMUMAB;
CP 751871;
TUMOR MARKER;
UNCLASSIFIED DRUG;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER SCREENING;
CANCER SURGERY;
CLINICAL TRIAL;
COST CONTROL;
DRUG RESEARCH;
GENE EXPRESSION;
GENETIC MARKER;
HUMAN;
MEDICAL RESEARCH;
NOTE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
TUMOR BIOPSY;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC PROTOCOLS;
BAYES THEOREM;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
FEMALE;
HUMANS;
MAGNETIC RESONANCE IMAGING;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 77952233260
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0510-383 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
